Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Investor Presentation (December 2006)
52 slides from Neuren Pharmaceuticals's investor presentation, Dec 5, 2006
Slide 1: Neuren's Partnering Update
pharmaceuticals Neuren’s Partnering Update 5 December 2006: Mr Larry Glass, Executive Vice President of Neuren Pharmaceuticals Ltd (ASX:NEU)} will this week be meeting with a variety of biotechnology companies in Europe to increase the awareness of the Company and to explore potential partnering opp
Slide 2: Soe
Soe
Slide 3: ies. ‘Suct
ies. ‘Suct tat may cause the actual to be materially SNM ANTANN NANA TAU ANIMA ANNA AANA i ag
Slide 4: Neuren Pharmaceuticals Ltd
armaceuticals Ltd ty of Auckland Ie I, 1) i hag wi CC
Slide 5: CNS Product Portfolio
CNS Product Portfolio ANH MANNA AN AANA MMMM AAA AA AAI
Slide 6: Glypromate
Slide 7: Small molecule
3 — Small mole Highly di 0 Hil el CE Se
Slide 8: Modes of Action
ih . Modes of Action dependent apoptosis dary He fT) Te iat i i @ CC
Slide 9: ited secondary
ited secondary de hn 0 (se Gi raul D : _ CC
Slide 10: Glypromate is Neuroprotective
omate is Neuroprotective sute Brain Injury Glypromate treatment (3 mg/kg/h i.v. infusion) WA Vehicle (n = 17) Glypromate (n = 19) P < 0.001 | I I Striatum CA1/2 CA3 CA4 DG Cortex Brain Region bd —_ l Tissue Damage Score nN 1 ?
Slide 11: Efficacy of Glypromate in MCAO
of Glypromate in MCAO 4, Zaz Control (n = 15) 505 wz Control (n = 15) Glypromate (n = 16) (3/18 rats died) (3 Glypromate (n = 16) (0/16 rats died) 24 07 EinZ=EEEy -24 (P = 0.004) (P = 0.02) 4 % Body weight gain Control Glypromate > : CE Se
Slide 12: Glypromate
@ 6 ~" Blypromate® £ 65 —— Saline control S 28 ‘oO 84 “—" Glypromate® oe —=— Normal 2 —= Saline cans) 8 Se 2° 28° g Pe > g 2 *P< 0.05 © a B14 21 os ° : T 15 0 5 10 Days post injury Days post injury
Slide 13: Clinical Program
© Clinical Program nu iple dose ‘i 1 st le Sein Ju Le he ql Wil ) ae CC
Slide 14: Me : if ia a :
aN Me : if ia a : = a ; meurer_ otitis ANAM ee
Slide 15: Dosing schedule and study design
g sched s, dose- escalation) or 2006 2006 tinuous infusion) (i IM i HN Nia - : — ANON
Slide 16: NNZ-2566 vs Vehicle
P= 0.004 Vehicle Mill NNZ-2566 CC
Slide 17: Beam Walk Test (Foot Fault)
Nn ce eam Fest (Foot Fault nig Bil Te i 8 AG 1) CC
Slide 18: CC
CC
Slide 19: Performance
erfor .. 70% * Mt wi MEER Ties i aie 000 Bim ae CC
Slide 20: Vehicle and dose groups
Bf vehicle 3mg/kg/h x 12h Ey 10.mg/kg + 3mg/kg/h x 12h a Deeks + 3mg/kg/h x 24h meuren} CC
Slide 21: Attenuation of Non-Convulsive Seizures
ten ation of Non- Convulsive Seizures oe al a In se Total Time'-Mean Time —_ Latency meuren} CC
Slide 22: NCS Incidence
HHI, & MN _NCS Incidence (1213) CC
Slide 23: Total NCS activity
otal NCS activity neuren
Slide 24: NCS frequency
NCS frequency AH HHI, AN — eee
Slide 25: Bolus dose groups
Vehicle 3mg/kg bolus 1Ome/kg bolus 100mg/kg bolus
Slide 26: MAH
MAH ZINN
Slide 27: oe — ee
oe — ee
Slide 28: Study in TBI patients
study in TBI patients with wy 0 an ei CC
Slide 29: Within-subjects comparisons
Within- -subjects comparisons epileptiform al EEG percent alphe va ‘ability (PAV) score ' neasured in CSF at 2 Bt! 72, 96 hrs) down orca & as spase- 1 ihe 5h S . 2 i a OT i Sa ifs ig AU HANG i ANON
Slide 30: Cohort Comparisons
: Cohort Comparisons We all le all PUR iF a i CC
Slide 31: Study 2: Phase IIa (mild-moderate)
Slide 32: Oral: Bioavailability
ral: Bioavailability emulsion CC
Slide 33: Oral (single dose)
ral (single dose) MCAO-Induced Ischaemic Brain Damage: Effect of Oral NNZ-2566 ae 80 + Damage (mm2) Pneuren), CNC
Slide 34: “Unpaired t test
66 “Unpaired t test “Pvalue 0.05) CC
Slide 35: Oral (2 doses)
Oral (2 doses) q =3.286 ct er meuren} CC loo eo ne
Slide 36: Protects Striatum and Cortex
tects Striatum and Cortex Oral Administration of - Cortical CC
Slide 37: Memory retention
Yemory retention treatment —e— 4 nonth Control —— 12 Month Contol 3 weeks (s-c.) =*+DF-+ 12 Month NNZ-2566 40 5 | Mean Swim Time to Platform (s) Retention 4 2 3 eT Test Day ave" } —_E__w_£_LL TT NNN NE EE AL GLITsH eT Te IOl) al
Slide 38: Function retained in rats
tion retained in rats Ei Post-stroke Vehicle 7 @Post-stroke NNZ-2566 Infarct Area (mm2) UN lit, CC
Slide 39: NNZ-2591
Ze tw =| CC y coe
Slide 40: Pharmacokinetics of NNZ-2591
y of NNZ-2591 NNZ-2591 (ug/ml) Hi 30 mg/kg IV Hl 30 mg/kg Oral N oO = oO On T T T r 60 Time (min) nihil Wise? AIC a yroril CC aa
Slide 41: Chronic effects in Parkinson's disease
Chronic effects in son’s disease LR ratio adjusted steps (%) a 68 400 7 Days Treatment with NNZ-2591(i.p.) ; shown by blue bar —0— Vehicle T T 4 6 8 10 12 Weeks post 6-OHDA lesion CC
Slide 42: Anti-Parkinsonian effects
4 anti-Parkinsonian s cent 400 icle (n=8) abv eniigin=®) a —A~ NNZ 2591 (n=8) LIR ratio adjusting steps (%) CC
Slide 43: Histopathology
4 Adm inistration: Histopathology #5 of variance means signif efferent? (P < 0.05 at a i hi CC
Slide 44: ote
ote
Slide 45: inna
2 inna ac CC
Slide 46: Acquisition and Probe trial
Acquisition —O= Saline / water Probe trial: —O= Saline / NNZ-2591 i Scopolamine / water —l- Scopolamine / NNZ-2591 Time to platform (seconds) Time to Platform Latency to Platform Quadrant LJ Scopolamine a Scopolamine + NNZ-2591 CL] Saline 7a Scopolamine CC oe Scopolamine + NNZ-2591
Slide 47: CC y coe
tw =| CC y coe
Slide 48: Neural Regeneration Peptides - NRPs
ler a Peptides - NRPs ee vel mouse Nrp gene encoding a Neural leuronal su al-promoting factor oe 24amino acids) alla ht i a= bali inn et a 4 — eee
Slide 49: Peripheral Neuropathy Model
35.00 Rp RP @B Ss & & o ¢ 8 &€ 8 15.00 Beam Walk Score (7 Steps) Vehicle MNNZ-4921 Day 0 Day 13 Severity Score Test Day (Pyridoxine days 1-8; NRP days 1-10} Day 24 110.0 105.0 100.0 95.0 90.0 85.0 + a Peripheral Neuropathy Model % Pre-PDX Body Weight Saline or NRP —a- Vehicle a NNZ-4921 1 23 4 5 6 7
Slide 50: meuren t~—
meuren t~— ANAM
Slide 51: Induced by cancer cells
luced by cancer cells maligr ant phenotype, En net ae ANON
Slide 52: Development Strategy
evelopment Strategy stratio func meuren} CC
Neuren Pharmaceuticals — Investor Presentation (December 2006) on 6ix